A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Huber, Bettina ^a   Schellenbacher, Christina ^a   Jindra, Christoph ^a   Fink, Dieter ^b   Shafti Keramat, Saeed ^a   Kirnbauer, Reinhard ^a  

^a Universitatsklinik fur Dermatologie   (Austria)

^b UNIVERSITY OF VETERINARY MEDICINE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN L1; CAPSID PROTEIN L2; EPITOPE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE VACCINE; VIRUS ANTIBODY; VIRUS PROTEIN; WART VIRUS VACCINE;

ALPHAPAPILLOMAVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; GENITAL TRACT INFECTION; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 39; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 59; HUMAN PAPILLOMAVIRUS TYPE 68; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; INFECTION RESISTANCE; MOUSE; NEW ZEALAND RABBIT; NONHUMAN; PAPILLOMAVIRUS INFECTION; PASSIVE IMMUNIZATION; VIRUS LIKE AGENT; AMINO ACID SEQUENCE; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CROSS PROTECTION; CYTOLOGY; GENETICS; HEK293 CELL LINE; HUMAN; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; PAPILLOMAVIRUS INFECTIONS; RABBIT; SF9 CELL LINE; TH1 CELL;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPES; MIRIDAE; MUS; ORYCTOLAGUS CUNICULUS; PAPILLOMAVIRIDAE;

ALPHAPAPILLOMAVIRUS; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CROSS PROTECTION; EPITOPES; FEMALE; HEK293 CELLS; HUMAN PAPILLOMAVIRUS 18; HUMANS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RABBITS; SF9 CELLS; TH1 CELLS; VACCINES, VIRUS-LIKE PARTICLE; VIRAL PROTEINS;

EID: 84925624862     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0120152     Document Type: Article

References (49)

1. Bernard HU, Burk RD, Chen Z, van Doorslaer K, Hausen H, de Villiers EM. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology. 2010; 401: 70-79. doi: 10.1016/j.virol.2010.02.002 PMID: 20206957
2. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010; 11: 1048-1056. doi: 10.1016/S1470-2045(10)70230-8 PMID: 20952254
3. Roden R, Wu TC. How will HPV vaccines affect cervical cancer? Nat Rev Cancer. 2006; 6: 753-763. PMID: 16990853
4. Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, de Sanjose S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010; 202: 1789-1799. doi: 10.1086/657321 PMID: 21067372
5. Alphs HH, Gambhira R, Karanam B, Roberts JN, Jagu S, Schiller JT, et al. Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc Natl Acad Sci U S A. 2008; 105: 5850-5855. doi: 10.1073/pnas.0800868105 PMID: 18413606
6. Jagu S, Karanam B, Gambhira R, Chivukula SV, Chaganti RJ, Lowy DR, et al. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst. 2009; 101: 782-792. doi: 10.1093/jnci/djp106 PMID: 19470949
7. Rubio I, Seitz H, Canali E, Sehr P, Bolchi A, Tommasino M, et al. The N-terminal region of the human papillomavirus L2 protein contains overlapping binding sites for neutralizing, cross-neutralizing and non-neutralizing antibodies. Virology. 2011; 409: 348-359. doi: 10.1016/j.virol.2010.10.017 PMID: 21074234
8. Gambhira R, Jagu S, Karanam B, Gravitt PE, Culp TD, Christensen ND, et al. Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. J Virol. 2007; 81: 11585-11592. PMID: 17715230
9. Tumban E, Peabody J, Peabody DS, Chackerian B. A universal virus-like particle-based vaccine for human papillomavirus: Longevity of protection and role of endogenous and exogenous adjuvants. Vaccine. 2013; 31: 4647-4654. doi: 10.1016/j.vaccine.2013.07.052 PMID: 23933337
10. Pastrana DV, Gambhira R, Buck CB, Pang YY, Thompson CD, Culp TD, et al. Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. Virology. 2005; 337: 365-372. PMID: 15885736
11. Slupetzky K, Gambhira R, Culp TD, Shafti-Keramat S, Schellenbacher C, Christensen ND, et al. A pap-illomavirus- like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. Vaccine. 2007; 25: 2001-2010. PMID: 17239496
12. Gaukroger JM, Chandrachud LM, O'Neil BW, Grindlay GJ, Knowles G, Campo MS. Vaccination of cattle with bovine papillomavirus type 4 L2 elicits the production of virus-neutralizing antibodies. J Gen Virol. 1996; 77 (Pt 7): 1577-1583. PMID: 8758002
13. Roden RB, Yutzy WHt, Fallon R, Inglis S, Lowy DR, Schiller JT. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology. 2000; 270: 254-257. PMID: 10792983
14. Kawana K, Yoshikawa H, Taketani Y, Yoshiike K, Kanda T. Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6. J Virol. 1999; 73: 6188-6190. PMID: 10364381
15. Jagu S, Kwak K, Garcea RL, Roden RB. Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection. Vaccine. 2010; 28: 4478-4486. doi: 10.1016/j.vaccine.2010.04.039 PMID: 20434552
16. Kondo K, Ochi H, Matsumoto T, Yoshikawa H, Kanda T. Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes. J Med Virol. 2008; 80: 841-846. doi: 10. 1002/jmv.21124 PMID: 18360909
17. Schellenbacher C, Kwak K, Fink D, Shafti-Keramat S, Huber B, Jindra C, et al. Efficacy of RG1-VLP vaccination against Infections with genital and Cutaneous Human Papillomaviruses. J Invest Dermatol. 2013; 133(12): 2706-13. doi: 10.1038/jid.2013.253 PMID: 23752042
18. Kirnbauer R, Schellenbacher C, Shafti-Keramat S, Handisurya A. HPV infections of the oral and genital mucosa. Possibilities for primary prevention. Hautarzt. 2009; 60: 878-880. doi: 10.1007/s00105-009-1803-4 PMID: 19862489
19. Gambhira R, Karanam B, Jagu S, Roberts JN, Buck CB, Bossis I, et al. A protective and broadly crossneutralizing epitope of human papillomavirus L2. J Virol. 2007; 81: 13927-13931. PMID: 17928339
20. Liu S, Semenciw R, Mao Y. Cervical cancer: the increasing incidence of adenocarcinoma and adenosquamous carcinoma in younger women. CMAJ. 2001; 164: 1151-1152. PMID: 11338801
21. Ronco G, Dillner J, Elfstrom KM, Tunesi S, Snijders PJ, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014; 383: 524-532. doi: 10.1016/S0140-6736(13)62218-7 PMID: 24192252
22. Smith HO, Tiffany MF, Qualls CR, Key CR. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States-a 24-year population-based study. Gynecol Oncol. 2000; 78: 97-105. PMID: 10926787
23. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189: 12-19. PMID: 10451482
24. Vinokurova S, Wentzensen N, Kraus I, Klaes R, Driesch C, Melsheimer P, et al. Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res. 2008; 68: 307-313. doi: 10.1158/0008-5472.CAN-07-2754 PMID: 18172324
25. Wheeler CM, Hunt WC, Joste NE, Key CR, Quint WG, Castle PE. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst. 2009; 101: 475-487. doi: 10.1093/jnci/djn510 PMID: 19318628
26. Castellsague X, Diaz M, de Sanjose S, Munoz N, Herrero R, Franceschi S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst. 2006; 98: 303-315. PMID: 16507827
27. Andersson S, Rylander E, Larsson B, Strand A, Silfversvard C, Wilander E. The role of human papillomavirus in cervical adenocarcinoma carcinogenesis. Eur J Cancer. 2001; 37: 246-250. PMID: 11166153
28. Buck CB, Pastrana DV, Lowy DR, Schiller JT. Efficient intracellular assembly of papillomaviral vectors. J Virol. 2004; 78: 751-757. PMID: 14694107
29. Buck CB, Thompson CD. Production of papillomavirus-based gene transfer vectors. Curr Protoc Cell Biol. 2007; Chapter 26: Unit 26. 21.
30. Kirnbauer R, Taub J, Greenstone H, Roden R, Durst M, Gissmann L, et al. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol. 1993; 67: 6929-6936. PMID: 8230414
31. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A. 1992; 89: 12180-12184. PMID: 1334560
32. Hagensee ME, Yaegashi N, Galloway DA. Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J Virol. 1993; 67: 315-322. PMID: 8380079
33. Day PM, Pang YY, Kines RC, Thompson CD, Lowy DR, Schiller JT. A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies. Clin Vaccine Immunol. 2012; 19: 1075-1082. doi: 10.1128/CVI.00139-12 PMID: 22593236
34. Roberts JN, Buck CB, Thompson CD, Kines R, Bernardo M, Choyke PL, et al. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med. 2007; 13: 857-861. PMID: 17603495
35. Rizk RZ, Christensen ND, Michael KM, Muller M, Sehr P, Waterboer T, et al. Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types. J Gen Virol. 2008; 89: 117-129. PMID: 18089735
36. Bray F, Carstensen B, Moller H, Zappa M, Zakelj MP, Lawrence G, et al. Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomarkers Prev. 2005; 14: 2191-2199. PMID: 16172231
37. Vizcaino AP, Moreno V, Bosch FX, Munoz N, Barros-Dios XM, Parkin DM. International trends in the incidence of cervical cancer: I. Adenocarcinoma and adenosquamous cell carcinomas. Int J Cancer. 1998; 75: 536-545. PMID: 9466653
38. Sasieni P, Adams J. Changing rates of adenocarcinoma and adenosquamous carcinoma of the cervix in England. Lancet. 2001; 357: 1490-1493. PMID: 11377601
39. Pirog EC, Kleter B, Olgac S, Bobkiewicz P, Lindeman J, Quint WG, et al. Prevalence of human papillomavirus DNA in different histological subtypes of cervical adenocarcinoma. Am J Pathol. 2000; 157: 1055-1062. PMID: 11021808
40. Costa S, Negri G, Sideri M, Santini D, Martinelli G, Venturoli S, et al. Human papillomavirus (HPV) test and PAP smear as predictors of outcome in conservatively treated adenocarcinoma in situ (AIS) of the uterine cervix. Gynecol Oncol. 2007; 106: 170-176. PMID: 17481701
41. Baalbergen A, Smedts F, Ewing P, Snijders PJ, Meijer CJ, Helmerhorst TJ. HPV-type has no impact on survival of patients with adenocarcinoma of the uterine cervix. Gynecol Oncol. 2013; 128: 530-534. doi: 10.1016/j.ygyno.2012.12.013 PMID: 23262207
42. Dabic MM, Nola M, Tomicic I, Dotlic S, Petrovecki M, Jukic S. Adenocarcinoma of the uterine cervix: prognostic significance of clinicopathologic parameters, flow cytometry analysis and HPV infection. Acta Obstet Gynecol Scand. 2008; 87: 366-372. doi: 10.1080/00016340801936560 PMID: 18307079
43. Malagon T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012; 12: 781-789. doi: 10.1016/S1473-3099(12)70187-1 PMID: 22920953
44. Kawana K, Matsumoto K, Yoshikawa H, Taketani Y, Kawana T, Yoshiike K, et al. A surface immunodeterminant of human papillomavirus type 16 minor capsid protein L2. Virology. 1998; 245: 353-359. PMID: 9636375
45. Varsani A, Williamson AL, de Villiers D, Becker I, Christensen ND, Rybicki EP. Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16. J Virol. 2003; 77: 8386-8393. PMID: 12857908
46. McGrath M, de Villiers GK, Shephard E, Hitzeroth II, Rybicki EP. Development of human papillomavirus chimaeric L1/L2 candidate vaccines. Arch Virol. 2013; 158: 2079-2088. doi: 10.1007/s00705-013-1713-8 PMID: 23636405
47. Seitz H, Dantheny T, Burkart F, Ottonello S, Muller M. Influence of oxidation and multimerization on the immunogenicity of a thioredoxin-l2 prophylactic papillomavirus vaccine. Clin Vaccine Immunol. 2013; 20: 1061-1069. doi: 10.1128/CVI.00195-13 PMID: 23677323
48. Pineo CB, Hitzeroth II, Rybicki EP. Immunogenic assessment of plant-produced human papillomavirus type 16 L1/L2 chimaeras. Plant Biotechnol J. 2013; 11: 964-975. doi: 10.1111/pbi.12089 PMID: 23924054
49. Clifford G, Franceschi S, Diaz M, Munoz N, Villa LL. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine. 2006; 24 Suppl 3: S3/26-34.